Menopause and metabolic dysfunction-associated steatotic liver disease
- PMID: 38760254
- DOI: 10.1016/j.maturitas.2024.108024
Menopause and metabolic dysfunction-associated steatotic liver disease
Abstract
Nonalcoholic fatty liver disease, recently proposed to be renamed metabolic dysfunction-associated steatotic liver disease, is a highly prevalent disease (25-30 % of the global general population) whose prevalence increases after menopause. Apart from the rates of simple steatosis, the severity of the disease (e.g., hepatic fibrosis) increases after menopause. Menopause is associated with higher abdominal adiposity and dysmetabolism of carbohydrate and lipid metabolism, which may contribute to the development and severity of metabolic dysfunction-associated steatotic liver disease and the higher cardiovascular risk observed after menopause. The association between menopause and metabolic dysfunction-associated steatotic liver disease renders menopausal hormone therapy an appealing way to reverse hepatic disease in parallel with the benefits of menopausal hormone therapy in other tissues. In this regard, most animal studies have shown a beneficial effect of estrogens on metabolic dysfunction-associated steatotic liver disease. Still, clinical studies are few, and their data are conflicting. The effect of menopausal hormone therapy on metabolic dysfunction-associated steatotic liver disease may be distinct among estrogen monotherapies and the combinations of estrogens and progestogens. It may also depend on the type of progestogen and the route of administration. However, more studies specifically designed for these aims are needed to draw secure conclusions. This review summarizes the data related to the association between menopause and metabolic dysfunction-associated steatotic liver disease, as well as between menopausal hormone therapy and metabolic dysfunction-associated steatotic liver disease, with a special focus on clinical studies.
Keywords: Cardiovascular disease; Insulin resistance; Menopausal hormone therapy; Metabolic dysfunction-associated steatotic liver disease; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare they have no competing interest.
Similar articles
-
Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease.Hormones (Athens). 2022 Sep;21(3):375-381. doi: 10.1007/s42000-022-00369-8. Epub 2022 May 9. Hormones (Athens). 2022. PMID: 35532850 Review.
-
Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives.Curr Vasc Pharmacol. 2019;17(6):546-555. doi: 10.2174/1570161116666180711121949. Curr Vasc Pharmacol. 2019. PMID: 29992886 Review.
-
Role of Estrogens in the Regulation of Liver Lipid Metabolism.Adv Exp Med Biol. 2017;1043:227-256. doi: 10.1007/978-3-319-70178-3_12. Adv Exp Med Biol. 2017. PMID: 29224098 Free PMC article. Review.
-
Hormone replacement therapy for steatotic liver management after surgical menopause.Clin J Gastroenterol. 2025 Apr;18(2):352-356. doi: 10.1007/s12328-024-02090-y. Epub 2025 Jan 6. Clin J Gastroenterol. 2025. PMID: 39760964
-
The menopause: benefits and risks of estrogen-progestogen replacement therapy.Fertil Steril. 1982 Apr;37(4):457-74. doi: 10.1016/s0015-0282(16)46149-2. Fertil Steril. 1982. PMID: 7040116 Review.
Cited by
-
Gut microbiota has the potential to improve health of menopausal women by regulating estrogen.Front Endocrinol (Lausanne). 2025 Jun 9;16:1562332. doi: 10.3389/fendo.2025.1562332. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40551890 Free PMC article. Review.
-
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women.Biomedicines. 2025 Apr 2;13(4):855. doi: 10.3390/biomedicines13040855. Biomedicines. 2025. PMID: 40299427 Free PMC article. Review.
-
Association Between Alpha-1-Acid Glycoprotein and Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Adult Women.Metabolites. 2025 Apr 17;15(4):280. doi: 10.3390/metabo15040280. Metabolites. 2025. PMID: 40278409 Free PMC article.
-
Relationship between serum uric acid levels and metabolism associated fatty liver disease in postmenopausal women based on NHANES 2017-2020.Sci Rep. 2025 Mar 15;15(1):8944. doi: 10.1038/s41598-025-93738-3. Sci Rep. 2025. PMID: 40089555 Free PMC article.
-
Excess cardiovascular mortality in men with non-alcoholic fatty liver disease: A cause for concern!World J Cardiol. 2024 Jul 26;16(7):380-384. doi: 10.4330/wjc.v16.i7.380. World J Cardiol. 2024. PMID: 39086893 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical